Navigation Links
University of Maryland School of Medicine receives $7.9 million grant for 'super' research magnet
Date:8/11/2010

The University of Maryland School of Medicine has received a $7.9 million federal grant to acquire a superconducting 950 MHz Nuclear Magnetic Resonance (NMR) magnet that will help researchers unravel the mysteries of molecules and develop new agents to treat cancer, AIDS and other diseases. The grant is among the largest of its kind ever awarded by the National Center for Research Resources (NCRR), which is part of the National Institutes of Health. The funds were made available through the American Recovery and Reinvestment Act of 2009.

The proposal to acquire the two-story spectrometer (with the super magnet) was a partnership between the University of Maryland, Baltimore (UMB), and two other University of Maryland campuses the University of Maryland, Baltimore County (UMBC) and the University of Maryland, College Park (UM). The instrument will be shared equally among the three campuses.

The University of Maryland will be the only academic institution in the United States and one of only two sites in the country to have a 950 MHz NMR spectrometer once it is installed in November of 2011.

David J. Weber, Ph.D., professor of biochemistry and molecular biology at the University of Maryland School of Medicine and director of the NMR core facility at UMB, is a co-director of the grant, along with Michael F. Summers, Ph.D., of UMBC, and David Fushman, Ph.D., of UM.

The eight-ton magnet produces a supercharged magnetic field that enables scientists to investigate the three-dimensional structure of biological molecules and study their interaction with the highest degree of resolution.

"NMR spectroscopy plays a critical role in many areas of cancer research, and having a 950 MHz NMR spectrometer on our campus is a phenomenal resource for researchers at our cancer center. It will greatly enhance and speed our efforts to uncover new information about cancer and design new drugs to treat it," says Kevin J. Cullen, M.D., director of the University of Maryland Marlene and Stewart Greenebaum Cancer Center, and professor of medicine and director of the Program in Oncology at the University of Maryland School of Medicine.

"We will be the only academic facility in the country to have this powerful magnet," says E. Albert Reece, M.D., Ph.D., M.B.A., vice president of medical affairs at the University of Maryland and dean of the University of Maryland School of Medicine. "This technology is a testament to our status as a world-class research institution. The magnet will be a critical tool in our mission to use the latest in cutting-edge technologies in our labs to bring lifesaving new treatments to patients in the clinic."

The 22.3 Tesla magnet is so powerful that it could lift 50 cars. The equipment will be housed in the UMB NMR core facility, located at the University of Maryland School of Medicine, and will be used by researchers from all three campuses as well as from institutions throughout the Mid-Atlantic region.

The instrument initially will have 35 users including 10 major core users and will operate 24 hours a day, seven days a week, according to Dr. Weber.

"Being able to observe molecules at the atomic-level eliminates a great deal of guessing when you're conducting complicated molecular experiments. We will have a much better ability to look at larger molecules and protein complexes with this powerful magnet it's like working in a room with the lights turned on," Dr. Weber says.

Dr. Weber's laboratory is developing small-molecule inhibitors geared to a family of calcium-binding proteins called S100 proteins, including one that currently is being tested in a clinical study at the cancer center as a possible treatment for melanoma. Other cancer center researchers are studying ways to help repair the DNA in cells that have been damaged by cancer.


'/>"/>

Contact: Karen E. Warmkessel
kwarmkessel@umm.edu
410-328-8919
University of Maryland Medical Center
Source:Eurekalert

Related biology news :

1. University of Maryland co-sponsors International Conference on the Effects of Noise on Aquatic Life
2. University of Maryland partnership receives $7.9M from NIH for superconducting research magnet
3. Ben-Gurion University of the Negev professor awarded the 2010 Elkeles Prize for Cancer Research
4. Hebrew University researchers identify gene related to chronic pain
5. Scientists at University of Colorado Anschutz Medical Campus discover new fat cell
6. NJIT professor receives Fulbright to study at University of Salerno
7. University of Hawaii completes 3-year investigation of military munitions sea disposal site
8. Ben-Gurion University of the Negev researchers identify risks of hypertension in young adults
9. University of Washington professors lifetime efforts receive international recognition
10. Kids could get more whole grains from after-school snacks, University of Minnesota study finds
11. Tulane University will receive $11.2 million to lead international malaria research center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology: